Trump and Biden Both Hate Pharma—Investors Shouldn't
The drug sector just had one of its worst years ever relative to the S&P 500 and now faces political attacks, but investors should focus on the value.
Stay updated with breaking news from Will Sevush. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The drug sector just had one of its worst years ever relative to the S&P 500 and now faces political attacks, but investors should focus on the value.
In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.
The pharmaceutical company’s silence on oral obesity drug worries investors
Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.
Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.